학술논문
A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adults
Document Type
Article
Author
Source
In: Vaccine . (Vaccine, 21 January 2022, 40(2):351-358)
Subject
Language
English
ISSN
18732518
0264410X
0264410X